VT-1161: Phase IIb started

Viamet began the double-blind, placebo-controlled, U.S. Phase IIb REVIVE trial to evaluate 150 and 300 mg oral VT-1161 once daily for 7 days followed by once-weekly dosing for 11 or 23 weeks in about ...